IMR Press / FBL / Volume 7 / Issue 4 / DOI: 10.2741/small

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Alzheimer's disease biomarkers: their value in diagnosis and clinical trials
Show Less
1 Laboratory of Molecular Neurobiology, Department of Pathology, University of Melbourne, Victoria 3010, Australia
Front. Biosci. (Landmark Ed) 2002, 7(4), 986–988; https://doi.org/10.2741/small
Published: 1 April 2002
Abstract

Biomarkers of Alzheimer's disease may be useful, not only for early diagnosis of the disease, but also for monitoring the progress of drug trials. A number of plasma and cerebrospinal fluid markers are reportedly altered in Alzheimer's disease. So far, no single biomarker can be used to diagnose Alzheimer's disease definitively. Nevertheless, it may eventually be possible to use several markers in combination to obtain sufficient diagnostic accuracy. However, for this to be the case, new specific biomarkers may need to be identified.

Keywords
Alzheimer's disease
Biomarker
CNS
Review
Share
Back to top